Bayer CEO Dekkers says price cuts threaten R&D

Bayer CEO Marijn Dekkers totted up a $2.7 billion price tag to research and develop the new anticoagulant Xarelto. And he's warning tight-fisted payers that the more they squeeze drug companies on product prices, the harder it will be to come up with important new treatments in the pipeline. "We need innovative pharmaceuticals more than ever, because so many known diseases still cannot be treated adequately, or at all, with medicines," Dekkers asserted as he warned that revenue is likely to stay largely flat in this financial environment. Story